Parkinson’s disease (PD) is an age-related neurodegenerative disorder. The degeneration of the neurons of the substantia nigra in the midbrain leads to the loss of dopamine from the striatum, which is responsible for the motor symptoms of PD. In the brain, the enzyme, monoamine oxidase B (MAOB), An analysis of the Lineweaver-Burk plots indicated that 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)- quinolinone inhibits MAO-B with a Ki value of 2.7 nM. An analysis of the structure-activity relationships for MAO-B inhibition shows that substitution on the C7 position of the 3,4-dihydro- 2(1H)-quinolinone moiety leads to significantly more potent inhibition compared to substitution on C6. In this regard, a benzyloxy substituent on C7 is more favourable than phenylethoxy and phenylpropoxy substitution on this position. In spite of this, C6-substituted 3,4-dihydro-2(1H)-quinolinone with potent MAO-B inhibitory activities were also identified. An analyses of selected properties of the 3,4-dihydro-2(1H)- quinolinones showed that the compounds are highly lipophilic with logP values in the range of 3.03- 4.55. LogP values between 1 and 3 are, however, in the ideal range for bioavailability. The compounds synthesised have logP values higher than 3, which may lead to lower bioavailability. Laboratory data further showed that none of the 3,4-dihydro-2(1H)-quinolinones are highly toxic to cultured cells at the concentrations, 1 μM and 10 μM, tested. For example, the most potent MAO-B inhibitor, 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone, reduced cell viability to 88.11% and 86.10% at concentrations of 1 μM and 10 μM, respectively. These concentrations are well above its IC50 value for the inhibition of MAO-B. At concentrations required for MAO-B inhibition, the more potent 3,4-dihydro-2(1H)-quinolinones are thus unlikely to be cytotoxic. It may thus be concluded that C7-substituted 3,4-dihydro-2(1H)-quinolinones are promising highly potent and selective MAO-B inhibitors, and thus leads for the therapy of Parkinson’s disease. represents a major catabolic pathway of dopamine. Inhibitors of MAO-B conserve the depleted supply of dopamine and are thus used in the therapy of PD. In the present study, a series of 3,4- dihydro-2(1H)-quinolinone derivatives were synthesized and evaluated as inhibitors of recombinant human MAO-A and MAO-B. These quinolinone derivatives are structurally related to a series of coumarin (1-benzopyran-2-one) derivatives, which has been reported to act as MAO-B inhibitors. C6- and C7-substituted 3,4-dihydro-2(1H)-quinolinone derivatives were synthesized by reacting 6- or 7- hydroxy-3,4-dihydro-2(1H)-quinolinone with an appropriately substituted alkyl bromide in the presence of base. To evaluate the MAO inhibitory properties (IC50 values) of the quinolinone derivatives the recombinant human MAO-A and MAO-B enzymes were used. The reversibility of inhibition of a representative 3,4-dihydro-2(1H)-quinolinone derivative was examined by measuring the recovery of enzyme activity after the dilution of the enzyme-inhibitor complexes, while the mode of MAO inhibition was determined by constructing Lineweaver-Burk plots. To determine the lipophilicity of the 3,4-dihydro-2(1H)-quinolinone derivatives, the logP values were measured. The toxicity of the 3,4-dihydro-2(1H)-quinolinone derivatives towards cultured cells (cytotoxicity) was also measured. The results document that the 3,4-dihydro-2(1H)-quinolinone derivatives are highly potent and selective MAO-B inhibitors with most homologues exhibiting IC50 values in the nanomolar range. The most potent MAO-B inhibitor, 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone, exhibits an IC50 value of 2.9 nM with a 2750-fold selectivity for MAO-B over the MAO-A isoform. As a MAO-B inhibitor, this compound is approximately equipotent to the most potent coumarin derivative (IC50 = 1.14 nM) reported in literature. Since MAO-B activity could be recovered after dilution of enzyme-inhibitor mixtures, it may be concluded that 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)- quinolinone is a reversible MAO-B inhibitor. The Lineweaver-Burk plots constructed for the inhibition of MAO-B by 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone were linear and intersected on the y-axis. These data indicated that this compound also is a competitive MAO-B inhibitor. / MSc (Pharmaceutical Chemistry), North-West University, Potchefstroom Campus, 2014

MSc dissertation School of Chemistry Faculty of Science 0004984F / Many azapolycyclic aromatic ring systems, whether they are naturally occurring or synthetically made, display important biological activities. One important class of naturally occurring azapolycyclic aromatic ring systems are the dibenzopyrrocoline alkaloids, which contain an indole ring fused to an isoquinoline moiety, where they share a common nitrogen. The basic skeleton of these alkaloids is the indolo[2,1-a]isoquinoline nucleus. Both the dibenzopyrrocoline alkaloids and the indolo[2,1-a]isoquinolines have been found to inhibit tubulin polymerization and thus possess antitumour and antileukemic activities. In our laboratories, a variety of indolo[2,1-a]isoquinolines, for example 5,12- dimethyl-6-phenylindolo[2,1-a]isoquinoline, have been synthesized using the Suzuki-Miyaura cross coupling reaction and reaction conditions for the formation of aromatic rings (KOBut in DMF and a light source – developed in our laboratories) as key steps. In this dissertation we discuss the synthesis of (±)-5,6-dihydro-6-phenylindolo[2,1-a]isoquinolin-5-ol and ethyl indolo[2,1- a]isoquinoline-6-carboxylate using these reaction conditions as our key steps. The syntheses commenced with the N-protection of isatin with a benzyl and an ethyl acetate group to afford 1-benzylindoline-2,3-dione and ethyl 2-(2,3- dioxoindolin-1-yl)acetate respectively. The next step was the synthesis of the brominated compounds 1-benzyl-2-bromo-1H-indole and ethyl 2-(2-bromo- 1H-indol-1-yl)acetate by means of a functional group interconversion of the oxygen in the 3-position to two chlorine atoms, followed by hydrodehalogenation, using zinc in AcOH, and then bromination, using POBr3 in CH2Cl2. Having obtained the brominated compounds we went on and coupled them with 2-formylphenylboronic acid using the Suzuki-Miyaura cross coupling reaction to obtain the coupled products 2-(1-benzyl-1H-indol-2- yl)benzaldehyde and ethyl 2-(2-(2-formylphenyl)-1H-indol-1-yl)acetate in 92 and 77% yield, respectively. Aromatisation of ethyl 2-(2-(2-formylphenyl)-1Hindol- 1-yl)acetate to ethyl indolo[2,1-a]isoquinoline-6-carboxylate occurred smoothly in 2 minutes using 10 mol % KOBut in DMF at room temperature. Using the same reaction conditions on 2-(1-benzyl-1H-indol-2- yl)benzaldehyde to form 6-phenylindolo-[2,1-a]isoquino-line resulted in (±)- 5,6-dihydro-6-phenylindolo[2,1-a]iso-quinolin-5-ol being obtained in 75% yield (7:3 ratio of anti:syn). An attempt to dehydrate this compound using p-TSA in CH2Cl2 in the presence of molecular sieves was not successful. Time constraints prevented any further attempts at dehydrating (±)-5,6-dihydro-6- phenylindolo[2,1-a]iso-quinolin-5-ol. In conclusion, we managed to synthesize (±)-5,6-dihydro-6-phenylindolo[2,1- a]isoquinolin-5-ol and ethyl indolo[2,1-a]isoquinoline-6-carboxylate using the Suzuki-Miyaura cross coupling reaction and specific reaction conditions, using the base KOtBu, for the formation of aromatic rings, both as key steps.

Cette thèse se divise en trois parties. La première concerne le développement d'une nouvelle voie d'accès à des hétérocycles azotés. Cette synthèse est basée sur deux étapes: l'addition radicalaire d'un xanthate, portant une fonction 1,2-dione, sur diverses oléfines suivie de sa condensation sur une diamine. Cette étude a permis de préparer des composés présentant un intérêt biologique certain tels que des pyrazines. De plus, une nouvelle méthodologie permettant l'accès à des structures imidazoles a été mise en évidence. La seconde partie a été consacrée à la préparation d'un support soluble à l'aide du procédé Madix. La dernière étude porte sur le développement de nouveaux agents modérateurs de la polymérisation radicalaire. Cette étude nous a amenés tout d'abord à synthétiser une large gamme de composés originaux de type dihydro-pyrazolone. Par la suite, la mise en place d'une étude modèle nous a permis de mesurer l'aptitude à se dissocier de ces composés puis de sélectionner les meilleurs candidats. Enfin, une étude poussée en polymérisation des agents sélectionnés a permis de mieux comprendre leur mécanisme d'action. Nous sommes en présence d'un système de type initer original. Ce système de polymérisation n'est cependant pas vivant du fait de l'irréversibilité de l'addition du contre radical dihydro-pyrazolone sur la chaîne polymère.

Les oxydations sur les bases nucléiques constituent l'une des sources principale d'apparition de lésions sur l'ADN, qui peuvent être mutagènes ou létales pour les cellules en l'absence de réparation de l'ADN. La Formamidopyrimidine-ADN glycosylase (Fpg), une enzyme procaryote du système de réparation de l'ADN par excision de base (BER), initie la réparation d'un large panel de lésions de ce type via ses activités ADN glycosylase (excision de la base oxydée) et AP lyase (clivage du site abasique par β,δ-élimination). Nous avons réalisé des études fonctionnelles par des techniques biochimiques et structurales par cristallographie des rayons X afin de préciser la spécificité de substrat et le mécanisme catalytique de Fpg. Ainsi, nous avons pu mettre en évidence des déterminants structuraux permettant à cette enzyme d'accommoder des lésions de tailles très différentes dans son site actif, en l'occurrence des résidus 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) substitués ou non en N7 par des adduits encombrants. D'autre part, nous avons caractérisé structuralement et fonctionnellement la reconnaissance et l'excision par Fpg d'une lésion pyrimidique, la 5-hydroxy-5-méthyle-hydantoïne (Hyd). Ainsi, nous avons montré que cette lésion appariée à une cytosine était un bon substrat pour l'enzyme, et nous avons précisé structuralement le mode de reconnaissance de l'Hyd par Fpg. D'autre part, nous avons mis en évidence un comportement inattendu de l'enzyme sur ce substrat. En l'occurrence, nous avons montré biochimiquement et structuralement qu'un pontage covalent se formait en quantités non négligeables entre Fpg et l'Hyd dans des conditions physiologiques. Mots clés : Réparation de l'ADN; Réparation par excision de base; Formamidopyrimidine-ADN glycosylase; 2,6- diamino-4-hydroxy-5-formamidopyrimidine; 7,8-dihydro-8-oxo-guanine; 5-hydroxy-5-méthyle-hydantoïne.

Les oxydations sur les bases nucléiques constituent l'une des sources principale d'apparition de lésions sur l'ADN, qui peuvent être mutagènes ou létales pour les cellules en l'absence de réparation de l'ADN. La Formamidopyrimidine-ADN glycosylase (Fpg), une enzyme procaryote du système de réparation de l'ADN par excision de base (BER), initie la réparation d'un large panel de lésions de ce type via ses activités ADN glycosylase (excision de la base oxydée) et AP lyase (clivage du site abasique par ß,d-élimination). Nous avons réalisé des études fonctionnelles par des techniques biochimiques et structurales par cristallographie des rayons X afin de préciser la spécificité de substrat et le mécanisme catalytique de Fpg. Ainsi, nous avons pu mettre en évidence des déterminants structuraux permettant à cette enzyme d'accommoder des lésions de tailles très différentes dans son site actif, en l'occurrence des résidus 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) substitués ou non en N7 par des adduits encombrants. D'autre part, nous avons caractérisé structuralement et fonctionnellement la reconnaissance et l'excision par Fpg d'une lésion pyrimidique, la 5-hydroxy-5-méthyle-hydantoïne (Hyd). Ainsi, nous avons montré que cette lésion appariée à une cytosine était un bon substrat pour l'enzyme, et nous avons précisé structuralement le mode de reconnaissance de l'Hyd par Fpg. D'autre part, nous avons mis en évidence un comportement inattendu de l'enzyme sur ce substrat. En l'occurrence, nous avons montré biochimiquement et structuralement qu'un pontage covalent se formait en quantités non négligeables entre Fpg et l'Hyd dans des conditions physiologiques.

Parkinson’s disease (PD) is an age-related neurodegenerative disorder. The degeneration of the neurons of the substantia nigra in the midbrain leads to the loss of dopamine from the striatum, which is responsible for the motor symptoms of PD. In the brain, the enzyme, monoamine oxidase B (MAOB), An analysis of the Lineweaver-Burk plots indicated that 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)- quinolinone inhibits MAO-B with a Ki value of 2.7 nM. An analysis of the structure-activity relationships for MAO-B inhibition shows that substitution on the C7 position of the 3,4-dihydro- 2(1H)-quinolinone moiety leads to significantly more potent inhibition compared to substitution on C6. In this regard, a benzyloxy substituent on C7 is more favourable than phenylethoxy and phenylpropoxy substitution on this position. In spite of this, C6-substituted 3,4-dihydro-2(1H)-quinolinone with potent MAO-B inhibitory activities were also identified. An analyses of selected properties of the 3,4-dihydro-2(1H)- quinolinones showed that the compounds are highly lipophilic with logP values in the range of 3.03- 4.55. LogP values between 1 and 3 are, however, in the ideal range for bioavailability. The compounds synthesised have logP values higher than 3, which may lead to lower bioavailability. Laboratory data further showed that none of the 3,4-dihydro-2(1H)-quinolinones are highly toxic to cultured cells at the concentrations, 1 μM and 10 μM, tested. For example, the most potent MAO-B inhibitor, 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone, reduced cell viability to 88.11% and 86.10% at concentrations of 1 μM and 10 μM, respectively. These concentrations are well above its IC50 value for the inhibition of MAO-B. At concentrations required for MAO-B inhibition, the more potent 3,4-dihydro-2(1H)-quinolinones are thus unlikely to be cytotoxic. It may thus be concluded that C7-substituted 3,4-dihydro-2(1H)-quinolinones are promising highly potent and selective MAO-B inhibitors, and thus leads for the therapy of Parkinson’s disease. represents a major catabolic pathway of dopamine. Inhibitors of MAO-B conserve the depleted supply of dopamine and are thus used in the therapy of PD. In the present study, a series of 3,4- dihydro-2(1H)-quinolinone derivatives were synthesized and evaluated as inhibitors of recombinant human MAO-A and MAO-B. These quinolinone derivatives are structurally related to a series of coumarin (1-benzopyran-2-one) derivatives, which has been reported to act as MAO-B inhibitors. C6- and C7-substituted 3,4-dihydro-2(1H)-quinolinone derivatives were synthesized by reacting 6- or 7- hydroxy-3,4-dihydro-2(1H)-quinolinone with an appropriately substituted alkyl bromide in the presence of base. To evaluate the MAO inhibitory properties (IC50 values) of the quinolinone derivatives the recombinant human MAO-A and MAO-B enzymes were used. The reversibility of inhibition of a representative 3,4-dihydro-2(1H)-quinolinone derivative was examined by measuring the recovery of enzyme activity after the dilution of the enzyme-inhibitor complexes, while the mode of MAO inhibition was determined by constructing Lineweaver-Burk plots. To determine the lipophilicity of the 3,4-dihydro-2(1H)-quinolinone derivatives, the logP values were measured. The toxicity of the 3,4-dihydro-2(1H)-quinolinone derivatives towards cultured cells (cytotoxicity) was also measured. The results document that the 3,4-dihydro-2(1H)-quinolinone derivatives are highly potent and selective MAO-B inhibitors with most homologues exhibiting IC50 values in the nanomolar range. The most potent MAO-B inhibitor, 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone, exhibits an IC50 value of 2.9 nM with a 2750-fold selectivity for MAO-B over the MAO-A isoform. As a MAO-B inhibitor, this compound is approximately equipotent to the most potent coumarin derivative (IC50 = 1.14 nM) reported in literature. Since MAO-B activity could be recovered after dilution of enzyme-inhibitor mixtures, it may be concluded that 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)- quinolinone is a reversible MAO-B inhibitor. The Lineweaver-Burk plots constructed for the inhibition of MAO-B by 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone were linear and intersected on the y-axis. These data indicated that this compound also is a competitive MAO-B inhibitor. / MSc (Pharmaceutical Chemistry), North-West University, Potchefstroom Campus, 2014

Conselho Nacional de Desenvolvimento Científico e Tecnológico / This dissertation first describes the collection of literature data among the years 2005 to 2011 for the subsequent data analysis of 1H NMR chemical shifts and coupling constants and 2JHH 3JHH with emphasis on the synthesis of 3,5-diaryl-4,5-dihydro-1H-pyrazoles. Initially, was analyzed the data from X-ray diffraction of compounds 4,5-dihydro-1H-pyrazoles with a focus on the molecular structure description. Posteriorly, the X-rays data was correlated with the 1H NMR chemical shifts observing the influence of different substituents on the pyrazole ring. The coupling constants 2JHH 3JHH were correlated with bond angles and dihedral angles observed respectively for the molecules of 3,5-diaryl-4,5-dihydro-1H-pyrazoles. / A presente dissertação descreve inicialmente a coleta de dados da literatura entre os anos de 2005 e 2011 para a posterior análise de dados de deslocamento químico de RMN 1H, e constantes de acoplamento 2JHH e 3JHH com ênfase à síntese de 3,5-diaril-4,5-diidro-pirazóis. Primeiramente, foram analisados os dados de difração de raios-X de compostos 4,5-diidro-1H-pirazóis com foco na estrutura molecular descrita. A seguir, correlacionou-se os dados de raios-X com os deslocamentos químicos de RMN 1H observando a influência dos diferentes substituintes sobre o anel pirazolínico. Foram correlacionadas as constantes de acoplamento 2JHH e 3JHH com os ângulos de ligação e ângulos diedros observados, respectivamente, para as moléculas de 3,5-diaril-4,5-diidro-1H-pirazóis.

No description available.

No description available.

Yes / The single enantiomer (1S,2S)-2-benzyl-2,3-dihydro-2-(1H-inden-2-yl)-1H-inden-1-ol (2), has recently been synthesized and isolated from its corresponding diastereoisomer (1). The molecular and crystal structures of this novel compound have been fully analyzed. The relative and absolute configurations have been determined by using a combination of analytical tools including X-ray crystallography, X-ray Powder Diffraction (XRPD) analysis and Nuclear Magnetic Resonance (NMR) spectroscopy. / Wellcome Trust